Since 2016, Alexander has been working in the field of cancer cell biology and antibody engineering, always in focus of developing new therapeutic approaches to overcome resistance mechanisms. Before starting at Anaveon in June 2022 he worked in a mid-size biotech company with a focus on the generation of antibody therapeutics in the field of immuno-oncology. In academia, he worked in close collaboration with different academic partners and research organizations. His principle scope of expertise is the development of bispecific antibodies, ranging from early screening of binders derived from phage display, immune NGS and immune library outputs, rational design, cloning, production and purification, biochemical and biophysical characterization, and their analyzes in vitro and in vivo.
- Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitorsNovember 1, 2023
- Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual MeetingOctober 16, 2023
- Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023